Clinical Trials Browser

Phase 1/2 × Withdrawn × brigatinib × Clear all

NCT04260009 2020-03-05

Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Phase 1/2 Withdrawn

Lymphoma, Large-Cell, Anaplastic